Financial Data and Key Metrics Changes - Company achieved strong results with sequential growth in bookings, revenue, EBITDA, and free cash flow, with revenue of $200 million at the top end of guidance range [6][18] - Free cash flow for Q2 was $23 million, totaling $30 million for the first half of the year, marking a 27% year-over-year increase [7][26] - Full year 2025 free cash flow guidance raised to between $60 million and $80 million, a $20 million increase [8][27] Business Line Data and Key Metrics Changes - Subsea product lines saw significant bookings, particularly for ROVs and a large submersible rescue vehicle system [6][19] - Artificial lift and downhole segment revenue increased by 6%, driven by demand for higher margin products [26] - Drilling and Completion segment revenue increased by 1%, with growth in coiled line pipe offerings [24] Market Data and Key Metrics Changes - U.S. revenue was up 3% despite a 3% decline in rig count, while international revenue (excluding Canada) increased by 6% [19] - Bookings were up 31% from the previous quarter, with a book-to-bill ratio of 132% [20] - Company expects commodity prices to remain stable, anticipating a gradual decline in industry activity [29] Company Strategy and Development Direction - Company has refined its strategy into leadership and growth markets, with leadership markets accounting for two-thirds of revenue and a 36% market share [10][11] - Growth markets, estimated to be twice the size of leadership markets, present significant opportunities for revenue increase [12][13] - The "Beat the Market" strategy aims to grow profitable market share through targeted competition and leveraging competitive advantages [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining momentum despite a declining rig count, supported by a strong backlog and cost reduction efforts [29][80] - The company anticipates continued strong free cash flow and plans to reduce net leverage to 1.3 times by year-end [28][29] - Management highlighted the potential for significant growth in the defense market and the importance of their operating systems in driving sales [66][69] Other Important Information - Company repurchased approximately 5% of shares outstanding in 2025, with plans to repurchase an additional 10% based on current stock price levels [8][28] - The company aims to balance capital returns with strategic investments, focusing on organic growth opportunities while remaining open to acquisitions [106] Q&A Session Summary Question: Timeframe for Doubling Market Share in Growth Markets - Management indicated that achieving this goal would take three to five years, focusing on customer acquisition and geographic expansion [37][38] Question: Details on Offshore Defense Orders - Management noted a mix of short-term and long-term products, with some orders expected to deliver over the next two years [39][40] Question: Expectations for Shares Outstanding in Q3 and Q4 - Management expects to repurchase an additional 1.2 million shares, potentially reducing shares outstanding by nearly 15% by December [48] Question: Factors Contributing to Increased Free Cash Flow Guidance - The primary driver for increased cash flow is expected to be working capital reduction, with improvements in operational efficiency [50][90] Question: Competitive Positioning and Market Outlook - Management emphasized a strong balance sheet and the ability to invest in growth, positioning the company favorably against competitors [110][111]

Financial Data and Key Metrics Changes - The company raised over $1 billion in cash through equity capital fundraising and structured finance, providing a strong financial foundation for commercialization and R&D activities [21][54][55] - The company ended the year with over $1 billion on its balance sheet, reflecting prudent financial planning [54][55] Business Line Data and Key Metrics Changes - Aficamtan is positioned as the anchor of the emerging specialty cardiology franchise, with ongoing clinical trials showing promising results [20][19] - The MAPLE HCM trial met its primary efficacy endpoint, demonstrating significant improvement in peak oxygen uptake compared to metoprolol [19][27] Market Data and Key Metrics Changes - The obstructive HCM market is now estimated to be closer to a 50/50 split with non-obstructive HCM, indicating a growing market opportunity [34] - The company aims to achieve access to over 100,000 patients in the coming years, emphasizing equitable and affordable access to its medicines [24] Company Strategy and Development Direction - The company’s Vision 02/1930 outlines a five-year strategic plan focused on innovation, access, and advancing research to benefit patients and shareholders [16][17] - The strategy includes a focus on specialty cardiology, with plans to advance multiple therapies targeting underserved patient populations [20][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the distinct benefit-risk profile of aficamtan despite the FDA extending the PDUFA date to December 2025 [18] - The company is optimistic about the potential for multiple product approvals and label expansions in the coming years [22][30] Other Important Information - The company is engaging with payers to design health economic studies and budget impact models to facilitate market access for aficamtan [42] - Partnerships with Bayer in Japan and Sanofi in China are part of the global strategy to ensure broad availability of aficamtan [43] Q&A Session Summary Question: What are the expectations for aficamtan's market entry? - The company is preparing for a potential market launch of aficamtan by the end of the year, with ongoing engagement with regulatory authorities [44][59] Question: How does the company plan to address payer concerns? - The company is designing studies to demonstrate the economic advantages of aficamtan, understanding payer motivations to ensure successful market access [42] Question: What is the significance of the recent clinical trial results? - The positive results from the MAPLE HCM trial are expected to be presented at a major medical meeting, potentially enabling expanded labeling for aficamtan [44][27]